Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix BioTherapeutics will present and join a webcast fireside chat at two New York investor conferences in mid-September 2026.

Rhea-AI Summary

Protalix BioTherapeutics (PLX)/b) will participate in two investor conferences in New York City in mid-September 2026.Senior Vice President and Chief Financial Officer Gilad Mamlok is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, with the company presentation set for Monday, September 14, 2026 at 2:00 p.m. EDT. He will also join a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, also running September 14-16, 2026, on Wednesday, September 16, 2026 at 1:05 p.m. EDT.

A live audio webcast and archived replay of the Morgan Stanley fireside chat will be accessible via a provided webcast link and through the Events Calendar in the Investors section of the Protalix website.

Key Figures

H.C. Wainwright conference: September 14-16, 2026 Morgan Stanley conference: September 14-16, 2026

H.C. Wainwright conference

September 14-16, 2026

Company presentation scheduled for September 14, 2026 at 2:00 p.m. EDT

Morgan Stanley conference

September 14-16, 2026

Fireside chat scheduled for September 16, 2026 at 1:05 p.m. EDT

Key Terms

enzyme replacement therapies, pegylated uricase, phase 2, dnase i

4 terms

enzyme replacement therapies medical

"researched, developed, and currently manufactures two enzyme replacement therapies"

Enzyme replacement therapies are medical treatments that supply patients with missing or malfunctioning enzymes by administering lab-made versions, often through regular infusions. Like replacing a broken part in a machine to restore normal function, these therapies can transform chronic, debilitating conditions into manageable ones; for investors they matter because they often command high prices, face strict regulatory and manufacturing hurdles, and can drive predictable long-term revenue if widely adopted.

pegylated uricase medical

"a plant cell-expressed recombinant PEGylated uricase for the treatment"

A pegylated uricase is a biologic drug made by attaching polyethylene glycol (PEG) chains to the enzyme uricase, which breaks down uric acid. The pegylation makes the enzyme last longer in the bloodstream and reduces immune reactions, so it can lower very high uric acid levels when standard treatments fail. Investors care because pegylated uricases are advanced therapeutic products subject to clinical trials, manufacturing complexity, and regulatory review, all of which affect commercial prospects.

phase 2 medical

"currently in the Phase 2 RELEASE trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

dnase i medical

"a plant cell-expressed long-acting DNase I for the treatment"

DNase I is an enzyme that cuts DNA strands into smaller pieces, like molecular scissors that break long threads into shorter fragments. For investors, DNase I matters because it is used in medical treatments, laboratory tests and manufacturing processes; changes in clinical trial results, regulatory approval, patent control, or production capacity can affect companies’ revenues and costs in biotech, diagnostics and contract manufacturing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Company Presentation Date & Time: Monday, September 14, 2026, 2:00 p.m. EDT

Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 14-16, 2026
Fireside Chat Date & Time: Wednesday, September 16, 2026, 1:05 p.m. EDT

A live audio webcast of the Morgan Stanley fireside chat will be available at https://cc.webcasts.com/morg007/091426a_js/?entity=125_OG1TMTP, and on the Events Calendar of the Investors section of the Company's website, www.protalix.com. An archived replay will be available following the event.

For more information or to schedule a one-on-one meeting with management, please contact your conference representative.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are available in multiple markets. These recombinant therapeutic proteins are expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. Protalix's global partner for Elfabrio® (pegunigalsidase alfa-iwxj), approved for Fabry disease in the United States, the European Union, and additional markets, is Chiesi Global Rare Diseases. Elelyso® (taliglucerase alfa) for Gaucher disease is approved in 23 markets and partnered with Pfizer Inc. worldwide, with the exception of Brazil, where Protalix partners with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health. Protalix's development portfolio includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, currently in the Phase 2 RELEASE trial; PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases; and research programs in rare renal diseases. To learn more, please visit www.protalix.com.

For Investor Inquiries:

Mike Moyer, Managing Director
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-upcoming-september-2026-investor-conferences-302872165.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When and where is Protalix presenting at the H.C. Wainwright conference?

The H.C. Wainwright 28th Annual Global Investment Conference takes place in New York City from September 14-16, 2026. Protalix is scheduled to deliver its company presentation on Monday, September 14, 2026 at 2:00 p.m. EDT.

When is the Morgan Stanley fireside chat with Protalix, and how can it be accessed?

The Morgan Stanley 24th Annual Global Healthcare Conference will also be held in New York City from September 14-16, 2026. Protalix's fireside chat is scheduled for Wednesday, September 16, 2026 at 1:05 p.m. EDT. A live audio webcast will be available at the specified webcast URL and on the Events Calendar of the Investors section of the Protalix website, with an archived replay available after the event.

How can investors arrange one-on-one meetings with Protalix management at these conferences?

Investors who wish to schedule a one-on-one meeting with management during the conferences are instructed to contact their conference representative.